Spain agrees to reimburse Orchard’s gene therapy Libmeldy

Orchard Therapeutics has secured reimbursement from another European market for Libmeldy, an ex vivo gene therapy for the rare childhood disease metachromatic leukodystrophy (MLD) first approved in the EU in 2020.

The Interministerial Commission for the Pricing of Medicines in Spain has backed access by the Spanish National Health System (SNS) to Libmeldy (atidarsagene autotemcel) for all forms of early-onset MLD, including pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ), or early symptomatic early juvenile (ESEJ).

The Spanish agreement follows similar…